Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib: A 32-week open-label extension study with optional narrow-band ultraviolet B

Publication date: June 2018
Source:Journal of the American Academy of Dermatology, Volume 78, Issue 6
Author(s): Deep Joshipura, Abdulaziz Alomran, Pedro Zancanaro, David Rosmarin




https://ift.tt/2s3MLTL